Sign In
Buy ABCL
$5.72
-0.410 (-6.69%)
At Close: Jun 03, 2026
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?
10:42am, Monday, 01'st Jun 2026
Here is how AbCellera Biologics Inc. (ABCL) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
After Golden Cross, AbCellera Biologics Inc. (ABCL)'s Technical Outlook is Bright
10:55am, Friday, 29'th May 2026
From a technical perspective, AbCellera Biologics Inc. (ABCL) is looking like an interesting pick, as it just reached a key level of support. ABCL's 50-day simple moving average crossed above its 200-
Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to Trade
10:56am, Friday, 22'nd May 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 97.3% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, th
7 Healthcare AI Stocks Under $50 With Huge Upside Potential
07:35am, Monday, 18'th May 2026
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing.
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
10:41am, Thursday, 14'th May 2026
Here is how AbCellera Biologics Inc. (ABCL) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
AbCellera Biologics Inc. (ABCL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
12:20am, Thursday, 14'th May 2026
AbCellera Biologics Inc. (ABCL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call Transcript
06:27am, Tuesday, 12'th May 2026
AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call Transcript
AbCellera Biologics Q1 Earnings Call Highlights
07:08pm, Monday, 11'th May 2026
AbCellera Biologics NASDAQ: ABCL said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued prepar
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates
06:25pm, Monday, 11'th May 2026
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.15 per share a year ago.
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
04:05pm, Monday, 11'th May 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635.
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
09:00am, Monday, 20'th Apr 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call.
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
04:05pm, Wednesday, 01'st Apr 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026.
AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
03:42am, Monday, 23'rd Mar 2026
AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
03:15pm, Friday, 06'th Mar 2026
AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says
02:06am, Friday, 06'th Mar 2026
AbCellera Biologics (NASDAQ: ABCL) is positioning itself as a more pipeline-driven biotechnology company after more than a decade of platform investment, according to comments from Senior Director of
